The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...

The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 ...

Last night, two purchases of Moderna’s stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel’s company, called Boston Biotech Ventures, bought 102,821 shares for an ...

Connor Schoen, the leader of homelessness nonprofit Breaktime, engineered a $6.3 million deal to purchase the five-story ...

Moderna shares experienced a significant surge in trading on Thursday, posting a 5.58% gain in European markets and an impressive jump of up to 16% on the NASDAQ. This remarkable performance was ...

But in 2025, Moderna aims to reduce cash cost expenses by $1 billion, CEO Stéphane Bancel said at the J.P. Morgan Healthcare Conference in January. The company will report its 2024 full-year ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...

Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences and the appointment of vaccine skeptic Robert F. Kennedy Jr. as U.S ...